Cargando…
Signaling pathways and therapeutic interventions in gastric cancer
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death. Despite tremendous progress in diagnosis and therapeutic strategies and significant improvements in patient survival, the low malignancy stage is relatively asymptomatic and many GC cases are diagnosed at...
Autores principales: | Lei, Zi-Ning, Teng, Qiu-Xu, Tian, Qin, Chen, Wei, Xie, Yuhao, Wu, Kaiming, Zeng, Qianlin, Zeng, Leli, Pan, Yihang, Chen, Zhe-Sheng, He, Yulong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547882/ https://www.ncbi.nlm.nih.gov/pubmed/36209270 http://dx.doi.org/10.1038/s41392-022-01190-w |
Ejemplares similares
-
Understanding and targeting resistance mechanisms in cancer
por: Lei, Zi‐Ning, et al.
Publicado: (2023) -
Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
por: Wang, Jing-Quan, et al.
Publicado: (2020) -
Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
por: Wu, Zhuo-Xun, et al.
Publicado: (2021) -
Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer
por: Chen, Guochuang, et al.
Publicado: (2023) -
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)